Optimize Financial Inc Purchases Shares of 60,599 Trevi Therapeutics, Inc. $TRVI

Optimize Financial Inc bought a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 60,599 shares of the company’s stock, valued at approximately $554,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TRVI. Russell Investments Group Ltd. increased its stake in shares of Trevi Therapeutics by 194.5% in the second quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock worth $25,000 after buying an additional 2,996 shares during the period. Strs Ohio purchased a new position in shares of Trevi Therapeutics in the first quarter valued at about $52,000. AlphaQuest LLC bought a new position in shares of Trevi Therapeutics during the third quarter valued at about $80,000. Farther Finance Advisors LLC boosted its holdings in shares of Trevi Therapeutics by 15,969.1% during the second quarter. Farther Finance Advisors LLC now owns 8,838 shares of the company’s stock worth $48,000 after purchasing an additional 8,783 shares during the period. Finally, Catalyst Funds Management Pty Ltd purchased a new stake in shares of Trevi Therapeutics during the second quarter worth about $56,000. Institutional investors own 95.76% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a research report on Friday, January 9th. D. Boral Capital restated a “buy” rating and set a $19.00 target price on shares of Trevi Therapeutics in a report on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Wednesday, January 21st. Oppenheimer boosted their price objective on shares of Trevi Therapeutics from $23.00 to $24.00 and gave the company an “outperform” rating in a research report on Friday, November 14th. Finally, B. Riley raised shares of Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, November 17th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $21.10.

Trevi Therapeutics Trading Up 4.7%

TRVI opened at $11.48 on Wednesday. The company has a market cap of $1.47 billion, a price-to-earnings ratio of -31.03 and a beta of 0.94. The stock has a fifty day simple moving average of $12.02 and a two-hundred day simple moving average of $10.10. Trevi Therapeutics, Inc. has a 12-month low of $3.77 and a 12-month high of $14.39.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Thursday, November 13th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. On average, analysts predict that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.